The National Institutes of Health (NIH) will partner with drug companies to spur research on new treatments for opioid addiction and pain medications that are not addictive, according to The Wall Street Journal.

In an article in the New England Journal of Medicine, NIH Director Francis S. Collins and Nora D. Volkow, Director of the National Institute on Drug Abuse, said the NIH will join with drug companies to launch an initiative in three scientific areas: developing better overdose-reversal and prevention interventions to reduce mortality, saving lives for future treatment and recovery; finding new, innovative medications and technologies to treat opioid addiction; and finding safe, effective, nonaddictive interventions to manage chronic pain.

Collins and Volkow called for stronger versions of the opioid overdose antidote naloxone to counteract painkillers such as fentanyl and carfentanil, which are much more potent than heroin.